STOCK TITAN

[Form 4] GeneDx Holdings Corp. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

GeneDx Holdings Corp. (WGS) director Emily M. Leproust reported multiple transactions involving Restricted Stock Units (RSUs) on June 18, 2025:

  • Acquired 3,576 new RSUs that vest at the earlier of next annual shareholder meeting or first grant anniversary
  • Converted 12,924 RSUs into Class A Common Stock at $0 exercise price
  • Following these transactions, directly owns 21,276 shares of Class A Common Stock and 3,576 RSUs

These transactions appear to be part of the company's director compensation program, with RSUs converting to common stock upon vesting. The RSUs represent a contingent right to receive one share of Class A Common Stock upon settlement without consideration. All transactions were reported via Form 4 filing through an attorney-in-fact on June 23, 2025.

Emily M. Leproust, direttrice di GeneDx Holdings Corp. (WGS), ha comunicato diverse operazioni riguardanti Restricted Stock Units (RSU) il 18 giugno 2025:

  • Ha acquisito 3.576 nuove RSU che maturano al più presto tra la prossima assemblea annuale degli azionisti o il primo anniversario della concessione
  • Ha convertito 12.924 RSU in azioni ordinarie di Classe A con prezzo di esercizio pari a 0 $
  • Dopo queste operazioni, detiene direttamente 21.276 azioni ordinarie di Classe A e 3.576 RSU

Queste operazioni fanno parte del programma di compensazione per i direttori della società, dove le RSU si convertono in azioni ordinarie al momento della maturazione. Le RSU rappresentano un diritto condizionato a ricevere una azione di Classe A al momento della liquidazione senza alcun corrispettivo. Tutte le operazioni sono state segnalate tramite la presentazione del Modulo 4 da un procuratore il 23 giugno 2025.

Emily M. Leproust, directora de GeneDx Holdings Corp. (WGS), informó varias transacciones relacionadas con Unidades de Acciones Restringidas (RSU) el 18 de junio de 2025:

  • Adquirió 3,576 nuevas RSU que se consolidan en la fecha anterior entre la próxima junta anual de accionistas o el primer aniversario de la concesión
  • Convirtió 12,924 RSU en acciones comunes Clase A con un precio de ejercicio de $0
  • Tras estas transacciones, posee directamente 21,276 acciones comunes Clase A y 3,576 RSU

Estas transacciones parecen formar parte del programa de compensación para directores de la compañía, donde las RSU se convierten en acciones comunes al consolidarse. Las RSU representan un derecho contingente a recibir una acción común Clase A al momento de su liquidación sin contraprestación. Todas las transacciones fueron reportadas mediante la presentación del Formulario 4 a través de un apoderado el 23 de junio de 2025.

GeneDx Holdings Corp.(WGS)의 이사 Emily M. Leproust는 2025년 6월 18일 제한 주식 단위(RSU)와 관련된 여러 거래를 보고했습니다:

  • 다음 연례 주주총회 또는 최초 부여 기념일 중 빠른 시점에 권리가 확정되는 3,576개의 신규 RSU를 취득
  • 행사가격 $0로 12,924개의 RSU를 클래스 A 보통주로 전환
  • 이 거래들 이후 직접 보유한 클래스 A 보통주 21,276주와 RSU 3,576주

이 거래들은 회사 이사 보상 프로그램의 일부로 보이며, RSU는 권리 확정 시 보통주로 전환됩니다. RSU는 대가 없이 결제 시 클래스 A 보통주 1주를 받을 수 있는 조건부 권리를 나타냅니다. 모든 거래는 2025년 6월 23일 법률대리인을 통해 Form 4 제출로 보고되었습니다.

Emily M. Leproust, administratrice de GeneDx Holdings Corp. (WGS), a déclaré plusieurs transactions impliquant des Restricted Stock Units (RSU) le 18 juin 2025 :

  • Acquisition de 3 576 nouvelles RSU qui deviennent acquises à la date la plus proche entre la prochaine assemblée annuelle des actionnaires ou le premier anniversaire de l’attribution
  • Conversion de 12 924 RSU en actions ordinaires de Classe A au prix d’exercice de 0 $
  • Après ces transactions, détient directement 21 276 actions ordinaires de Classe A et 3 576 RSU

Ces opérations semblent faire partie du programme de rémunération des administrateurs de la société, les RSU se convertissant en actions ordinaires à l’acquisition. Les RSU représentent un droit conditionnel de recevoir une action de Classe A lors du règlement sans contrepartie. Toutes les transactions ont été déclarées via un dépôt du Formulaire 4 par un mandataire le 23 juin 2025.

Emily M. Leproust, Direktorin von GeneDx Holdings Corp. (WGS), meldete am 18. Juni 2025 mehrere Transaktionen im Zusammenhang mit Restricted Stock Units (RSUs):

  • Erwarb 3.576 neue RSUs, die entweder bei der nächsten jährlichen Hauptversammlung oder am ersten Jahrestag der Gewährung fällig werden
  • Wandelte 12.924 RSUs zu einem Ausübungspreis von 0 $ in Class A Stammaktien um
  • Besitzt nach diesen Transaktionen direkt 21.276 Class A Stammaktien und 3.576 RSUs

Diese Transaktionen scheinen Teil des Vergütungsprogramms für Direktoren des Unternehmens zu sein, wobei RSUs bei Fälligkeit in Stammaktien umgewandelt werden. Die RSUs stellen ein bedingtes Recht dar, bei Abwicklung eine Class A Stammaktie ohne Gegenleistung zu erhalten. Alle Transaktionen wurden am 23. Juni 2025 über ein Formular 4 durch einen Bevollmächtigten gemeldet.

Positive
  • None.
Negative
  • None.

Emily M. Leproust, direttrice di GeneDx Holdings Corp. (WGS), ha comunicato diverse operazioni riguardanti Restricted Stock Units (RSU) il 18 giugno 2025:

  • Ha acquisito 3.576 nuove RSU che maturano al più presto tra la prossima assemblea annuale degli azionisti o il primo anniversario della concessione
  • Ha convertito 12.924 RSU in azioni ordinarie di Classe A con prezzo di esercizio pari a 0 $
  • Dopo queste operazioni, detiene direttamente 21.276 azioni ordinarie di Classe A e 3.576 RSU

Queste operazioni fanno parte del programma di compensazione per i direttori della società, dove le RSU si convertono in azioni ordinarie al momento della maturazione. Le RSU rappresentano un diritto condizionato a ricevere una azione di Classe A al momento della liquidazione senza alcun corrispettivo. Tutte le operazioni sono state segnalate tramite la presentazione del Modulo 4 da un procuratore il 23 giugno 2025.

Emily M. Leproust, directora de GeneDx Holdings Corp. (WGS), informó varias transacciones relacionadas con Unidades de Acciones Restringidas (RSU) el 18 de junio de 2025:

  • Adquirió 3,576 nuevas RSU que se consolidan en la fecha anterior entre la próxima junta anual de accionistas o el primer aniversario de la concesión
  • Convirtió 12,924 RSU en acciones comunes Clase A con un precio de ejercicio de $0
  • Tras estas transacciones, posee directamente 21,276 acciones comunes Clase A y 3,576 RSU

Estas transacciones parecen formar parte del programa de compensación para directores de la compañía, donde las RSU se convierten en acciones comunes al consolidarse. Las RSU representan un derecho contingente a recibir una acción común Clase A al momento de su liquidación sin contraprestación. Todas las transacciones fueron reportadas mediante la presentación del Formulario 4 a través de un apoderado el 23 de junio de 2025.

GeneDx Holdings Corp.(WGS)의 이사 Emily M. Leproust는 2025년 6월 18일 제한 주식 단위(RSU)와 관련된 여러 거래를 보고했습니다:

  • 다음 연례 주주총회 또는 최초 부여 기념일 중 빠른 시점에 권리가 확정되는 3,576개의 신규 RSU를 취득
  • 행사가격 $0로 12,924개의 RSU를 클래스 A 보통주로 전환
  • 이 거래들 이후 직접 보유한 클래스 A 보통주 21,276주와 RSU 3,576주

이 거래들은 회사 이사 보상 프로그램의 일부로 보이며, RSU는 권리 확정 시 보통주로 전환됩니다. RSU는 대가 없이 결제 시 클래스 A 보통주 1주를 받을 수 있는 조건부 권리를 나타냅니다. 모든 거래는 2025년 6월 23일 법률대리인을 통해 Form 4 제출로 보고되었습니다.

Emily M. Leproust, administratrice de GeneDx Holdings Corp. (WGS), a déclaré plusieurs transactions impliquant des Restricted Stock Units (RSU) le 18 juin 2025 :

  • Acquisition de 3 576 nouvelles RSU qui deviennent acquises à la date la plus proche entre la prochaine assemblée annuelle des actionnaires ou le premier anniversaire de l’attribution
  • Conversion de 12 924 RSU en actions ordinaires de Classe A au prix d’exercice de 0 $
  • Après ces transactions, détient directement 21 276 actions ordinaires de Classe A et 3 576 RSU

Ces opérations semblent faire partie du programme de rémunération des administrateurs de la société, les RSU se convertissant en actions ordinaires à l’acquisition. Les RSU représentent un droit conditionnel de recevoir une action de Classe A lors du règlement sans contrepartie. Toutes les transactions ont été déclarées via un dépôt du Formulaire 4 par un mandataire le 23 juin 2025.

Emily M. Leproust, Direktorin von GeneDx Holdings Corp. (WGS), meldete am 18. Juni 2025 mehrere Transaktionen im Zusammenhang mit Restricted Stock Units (RSUs):

  • Erwarb 3.576 neue RSUs, die entweder bei der nächsten jährlichen Hauptversammlung oder am ersten Jahrestag der Gewährung fällig werden
  • Wandelte 12.924 RSUs zu einem Ausübungspreis von 0 $ in Class A Stammaktien um
  • Besitzt nach diesen Transaktionen direkt 21.276 Class A Stammaktien und 3.576 RSUs

Diese Transaktionen scheinen Teil des Vergütungsprogramms für Direktoren des Unternehmens zu sein, wobei RSUs bei Fälligkeit in Stammaktien umgewandelt werden. Die RSUs stellen ein bedingtes Recht dar, bei Abwicklung eine Class A Stammaktie ohne Gegenleistung zu erhalten. Alle Transaktionen wurden am 23. Juni 2025 über ein Formular 4 durch einen Bevollmächtigten gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leproust Emily M.

(Last) (First) (Middle)
C/O GENEDX HOLDINGS CORP.

(Street)
STAMFORD CT 06902

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/18/2025 M 12,924 A $0(1) 21,276 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 06/18/2025 A 3,576 (2) (2) Class A Common Stock 3,576 $0 3,576 D
Restricted Stock Unit (1) 06/18/2025 M 12,924 (2) (2) Class A Common Stock 12,924 $0 0 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
2. The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.
/s/ Bridget Brown, Attorney-in-Fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trading activity occurred at GeneDx Holdings (WGS) on June 18, 2025?

Director Emily M. Leproust acquired 12,924 shares of Class A Common Stock through the conversion of Restricted Stock Units (RSUs) at $0 per share, bringing her total direct ownership to 21,276 shares. Additionally, she was granted 3,576 new RSUs on the same date.

How many shares of WGS does Emily Leproust now own directly?

Following the reported transactions, Emily Leproust directly owns 21,276 shares of WGS Class A Common Stock, plus 3,576 unvested Restricted Stock Units that will convert to shares upon vesting.

What are the vesting terms for the new WGS RSUs granted to Emily Leproust?

The RSUs will vest at the earlier of: (a) the date of the next annual meeting of GeneDx's shareholders following the grant date, or (b) the first anniversary of the grant date, subject to Leproust continuing to provide services to the company through the vesting date.

When did Emily Leproust report this WGS stock transaction to the SEC?

The Form 4 was signed by Bridget Brown (Attorney-in-Fact) on June 23, 2025, and filed with the SEC on June 28, 2025, reporting the June 18, 2025 transactions.
GeneDx Holdings Corp

NASDAQ:WGS

WGS Rankings

WGS Latest News

WGS Latest SEC Filings

WGS Stock Data

3.34B
25.15M
12.46%
105.84%
12.12%
Diagnostics & Research
Services-health Services
Link
United States
STAMFORD